Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
The AD8 is a brief, eight-question screening tool designed to detect early cognitive decline and help identify whether someone has dementia or mild cognitive impairment rather than normal age-related memory lapses. It was developed specifically for this purpose by Washington University researchers and focuses on changes in cognitive function that family members and close contacts notice over time. Unlike longer cognitive tests that require a trained professional to administer, the AD8 can be completed quickly by an informant—typically a family member or caregiver who sees the person regularly—making it one of the most accessible screening tools available.
The test takes only about two minutes to complete and asks questions about eight different areas of cognitive change: memory problems, difficulty with familiar tasks, getting lost, confusion with time or date, trouble with medications or finances, repeating questions or stories, trouble finding words, and becoming lost in thought or withdrawn. If someone scores two or higher on the AD8, it suggests cognitive impairment may be present and further evaluation with a healthcare provider is warranted. For example, a daughter might notice her mother has been asking the same question three times during a single phone call or forgetting how to use the TV remote after using it the same way for years—the types of changes the AD8 specifically asks about.
Table of Contents
- What Makes the AD8 Test Different From Other Cognitive Screening Tools?
- How Reliable Is the AD8 Test for Detecting Early Dementia?
- The Role of Family Members and Caregivers in AD8 Screening
- Using the AD8 in Clinical Practice and Home Settings
- Limitations of the AD8 and When It May Miss Cognitive Decline
- How Healthcare Providers Use AD8 Results in Diagnosis
- The Future of Cognitive Screening and the AD8’s Place in It
- Conclusion
What Makes the AD8 Test Different From Other Cognitive Screening Tools?
The ad8 stands apart from other dementia screening tests because it relies entirely on reports from someone who knows the person well, rather than on direct testing of the individual. This informant-based approach has a major advantage: it captures real-world changes in daily functioning that the person themselves may not recognize or admit to. Someone with early dementia often lacks awareness of their own cognitive decline—a phenomenon called anosognosia—so their own account of their memory or thinking may be unreliable. A spouse or adult child, by contrast, notices when familiar routines break down or when something that used to be automatic now requires effort.
The AD8 differs significantly from the Mini-Cog, the Montreal Cognitive Assessment, or the Mini-Mental State Examination, which all require a healthcare provider to administer specific tests and observe how someone performs tasks. These tests take longer and require professional training to interpret. The AD8 is deliberately short and simple because it’s designed for primary care settings, memory clinics, or even home use—places where a full neuropsychological battery isn’t practical. However, this simplicity comes with a tradeoff: while the AD8 is good at signaling when something may be wrong, it doesn’t diagnose Alzheimer’s disease or any specific type of dementia. It’s a red flag that prompts further testing, not a definitive diagnosis.
How Reliable Is the AD8 Test for Detecting Early Dementia?
The AD8 has solid research backing for its reliability. Multiple studies have shown it can identify mild cognitive impairment and dementia with reasonable accuracy compared to more extensive cognitive testing—somewhere in the range of 80–90% sensitivity and specificity in research settings, depending on the population studied. Sensitivity means how well it catches people who actually have dementia; specificity means how well it avoids false alarms in people without dementia. That said, the AD8 works better in some situations than others, which is an important limitation to understand.
The test performs best when the informant (the person answering the questions) knows the individual well and sees them regularly—daily contact or at least several times a week. If someone is rating a parent they see only once a month, they may miss subtle changes or may not be aware of day-to-day struggles. The AD8 also can produce false positives in people with depression, which can cause confusion and cognitive complaints without actually being dementia, or in people taking medications that affect cognition. Cultural differences in how families report changes also matter; research suggests the AD8 may perform slightly differently across different populations, though studies continue to refine this understanding. For these reasons, an AD8 score above two is not a diagnosis—it’s always a signal to get a proper medical evaluation.
The Role of Family Members and Caregivers in AD8 Screening
The emphasis on the informant’s perspective in the AD8 puts family members in a critical role in early detection. Spouses, adult children, and close caregivers are often the first to notice the small shifts that signal cognitive change—misplacing keys more often than before, losing track of conversations, or struggling with tasks like online banking that used to be routine. These observations are more valuable than almost any brief office-based test because they reflect real patterns across weeks and months, not just performance on a single day. A person with early dementia might perform normally on a cognitive test in a doctor’s office yet repeatedly fail to manage their medications at home—exactly the kind of real-world decline the AD8 tries to capture.
This creates both opportunity and responsibility. When a family member completes the AD8 and finds a concerning score, they have concrete evidence to bring to a healthcare provider and can advocate for further evaluation. In some cases, the person with cognitive concerns may deny there’s a problem or resist seeing a doctor; the AD8 gives families a tool to validate their concerns and support the conversation about getting help. However, completing the AD8 also requires honesty and close observation, and sometimes family members minimize changes—either to avoid confronting a difficult diagnosis or because they’ve gradually adjusted to the person’s decline and no longer notice it. This is why healthcare providers often talk with both the person and an informant when evaluating cognition.
Using the AD8 in Clinical Practice and Home Settings
In medical offices and memory clinics, the AD8 often serves as a quick screening step before more extensive testing. A primary care doctor might have a patient or their family member fill out the AD8 during a routine visit, spending just two minutes on it, and use the result to decide whether to order more comprehensive cognitive testing or refer to a neurologist or geriatrician. This approach is practical and cost-effective—the AD8 itself is free or very low cost, and it prevents the overuse of expensive neuropsychological batteries on everyone over 65. Many primary care clinics now include the AD8 as part of their cognitive assessment toolkit, especially as awareness of the importance of early detection grows.
Outside the clinic, caregivers have increasingly used the AD8 at home to monitor changes over time, sometimes repeating it every few months or a year to track whether someone is staying stable or declining. This can be valuable for documenting change over time, especially when discussing concerns with healthcare providers. The comparison works differently from medical settings, though: a score of 2 or higher on one occasion in the clinic should prompt evaluation, but someone using the AD8 at home should also look for changes across multiple administrations rather than relying on a single score. Some digital health platforms and geriatric assessment programs have also begun incorporating AD8 scores, making it easier to track cognitive screening results over time as part of a broader health record.
Limitations of the AD8 and When It May Miss Cognitive Decline
While the AD8 is useful, it has real limitations that both patients and providers should understand. One significant issue is that it can miss cognitive changes that haven’t yet affected daily functioning—someone might have structural brain changes or early pathology visible on advanced imaging but still perform normally on both the AD8 and clinical cognitive testing. This is sometimes called preclinical dementia, and there’s active research on whether detecting it early and intervening would help, but for now, the AD8 and similar tools simply aren’t designed to catch this stage. Additionally, the AD8 works less well for people with limited education or non-native English speakers, as the questions may be harder to understand or cultural differences in how cognitive concerns are reported can affect scores.
Another limitation involves differentiation between types of cognitive decline. The AD8 can signal that someone has cognitive impairment, but it can’t distinguish between Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia, or other conditions—all of which may show similar cognitive symptoms but require different management approaches. A person might score high on the AD8 and actually have depression-related cognitive slowing, mild cognitive impairment that may never progress to dementia, or early-stage Parkinson’s disease affecting cognition. This is why the AD8 is always just the first step, not the final word.
How Healthcare Providers Use AD8 Results in Diagnosis
When someone scores 2 or higher on the AD8, a healthcare provider typically moves to the next stage of evaluation, which usually includes taking a detailed history from both the person and the informant, conducting a more thorough cognitive exam, ordering blood tests to rule out reversible causes of cognitive decline (vitamin B12 deficiency, thyroid disease, medication effects), and sometimes ordering imaging like an MRI or PET scan if Alzheimer’s disease is suspected. The AD8 alone cannot diagnose Alzheimer’s disease—that requires evidence of amyloid and tau pathology, which can now be detected through advanced blood biomarkers or brain imaging—but it reliably raises the question that needs to be investigated. A concrete example: a 68-year-old man’s wife completes the AD8 and reports he’s been getting lost while driving to familiar places, forgetting recent conversations, and struggling to pay bills online.
The AD8 score is 5. His doctor listens to both their accounts, gives him a more detailed cognitive test that also suggests impairment, and orders a blood test for phosphorylated tau—a biomarker associated with Alzheimer’s disease. If the biomarker is elevated and imaging shows typical Alzheimer’s pattern changes, he may be diagnosed with mild cognitive impairment due to Alzheimer’s disease or early-stage Alzheimer’s disease, depending on how much his daily functioning is affected. The AD8 was the gateway to this diagnosis, even though it wasn’t the tool that made it.
The Future of Cognitive Screening and the AD8’s Place in It
As dementia research advances, cognitive screening tools like the AD8 are evolving. Blood-based biomarkers for Alzheimer’s disease—such as phosphorylated tau and amyloid-beta ratios—can now be tested in routine clinical visits and are becoming more accessible. Some experts believe future screening might combine brief cognitive tools like the AD8 with optional biomarker testing to identify people at risk even earlier. The goal is to start interventions like disease-modifying medications, lifestyle changes, or cognitive training as soon as possible, when they may have the most impact.
The AD8 is likely to remain part of this toolkit because it’s simple, accessible, and captures information from family members that biomarkers alone cannot—the real-world functional changes that matter most to people living with cognitive decline. The landscape is also shifting toward more equitable screening, with ongoing efforts to adapt and validate tools like the AD8 across different languages and cultural contexts. Research continues to refine how we use informant-based screening in diverse populations and how we integrate it with emerging biomarker testing. The AD8 may not be the final word on cognitive screening ten years from now, but it remains a practical, evidence-based entry point for identifying cognitive change today.
Conclusion
The AD8 is a practical screening tool that uses information from family members and caregivers to identify potential cognitive impairment and prompt further medical evaluation. It excels at capturing real-world cognitive changes that happen outside the doctor’s office and can be completed in just two minutes, making it useful in busy primary care settings, memory clinics, and homes.
A score of 2 or higher suggests the need for more comprehensive cognitive and medical evaluation to determine whether someone has mild cognitive impairment, Alzheimer’s disease, or another condition affecting thinking. If you or a family member are concerned about cognitive changes, talking with a healthcare provider about your observations and potentially completing the AD8 is a concrete first step toward understanding what’s happening and what options are available. While the AD8 is not a diagnosis and has limitations, it has helped many people recognize early cognitive decline and access the evaluations, treatments, and support planning that can make a real difference in their quality of life.
